{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:12:58Z","timestamp":1787112778975,"version":"build-2736575974"},"reference-count":27,"publisher":"The Japanese Society for Medical Mycology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Mycology Journal"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3314\/mmj.16-00020","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T22:21:19Z","timestamp":1480371679000},"page":"J141-J147","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Characteristics of Two Topical Therapeutic Agents for Onychomycosis"],"prefix":"10.3314","volume":"57","author":[{"given":"Tsuyoshi","family":"Shimamura","sequence":"first","affiliation":[{"name":"R&D Laboratories, POLA PHARMA INC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miyamae","sequence":"additional","affiliation":[{"name":"R&D Laboratories, POLA PHARMA INC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Imai","sequence":"additional","affiliation":[{"name":"R&D Laboratories, POLA PHARMA INC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozue","family":"Hirayanagi","sequence":"additional","affiliation":[{"name":"R&D Laboratories, POLA PHARMA INC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Iwanaga","sequence":"additional","affiliation":[{"name":"R&D Laboratories, POLA PHARMA INC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Kubota","sequence":"additional","affiliation":[{"name":"R&D Laboratories, POLA PHARMA INC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Toho University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1842","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ghannoum MA, Hajjeh RA, Scher R, et al: A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 43: 641-648, 2000","DOI":"10.1067\/mjd.2000.107754"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ogasawara Y: Prevalence and patient&rsquo;s consciousness of tinea pedis and onychomycosis. Nihon Ishinkin Gakkai Zasshi 44: 253-260, 2003.","DOI":"10.3314\/jjmm.44.253"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Haneke E, Roseeuw D: The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 38(Suppl 2): 7-12, 1999.","DOI":"10.1046\/j.1365-4362.1999.00015.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"5) Belyayeva E, Gregoriou S, Chalikias J, Kontochristopoulos G, Koumantaki E, Makris M, Koti I, Katoulis A, Katsambas A, Rigopoulos D: The impact of nail disorders on quality of life. Eur J Dermatol 23: 366-371, 2013.","DOI":"10.1684\/ejd.2013.2048"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6) Schein JR, Gause D, Stier DM, Lubeck DP, Bates MM, Fisk R: Onychomycosis. Baseline results of an observational study. J Am Podiatr Med Assoc 87: 512-519, 1997.","DOI":"10.7547\/87507315-87-11-512"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7) Pires CA, Cruz NF, Lobato AM, Sousa PO, Carneiro FR, Mendes AM: Clinical, epidemiological, and therapeutic profile of dermatophytosis. An Bras Dermatol 89: 259-264, 2014.","DOI":"10.1590\/abd1806-4841.20142569"},{"key":"7","unstructured":"9) Daniel RC: Onychomycosis: burden of disease and the role of topical antifungal treatment. J Drugs Dermatol 12: 1263-1266, 2013."},{"key":"8","unstructured":"10) Elewski B, Tavakkol A: Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 1: 299-306, 2005."},{"key":"9","doi-asserted-by":"crossref","unstructured":"11) Tatsumi Y: Pharmacological characteristics and clinical results of efinaconazole (Clenafin&reg; Topical Solution 10%), a novel anti-onychomycosis drug. Nihon Yakurigaku Zasshi 145: 250-258, 2015.","DOI":"10.1254\/fpj.145.250"},{"key":"10","doi-asserted-by":"crossref","unstructured":"12) Elewski BE, Ghannoum MA, Mayser P, Gupta AK, Korting HC, Shouey RJ, Baker DR, Rich PA, Ling M, Hugot S, Damaj B, Nyirady J, Thangavelu K, Notter M, Parneix-Spake A, Sigurgeirsson B: Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol 27: 287-294, 2013.","DOI":"10.1111\/j.1468-3083.2011.04373.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"13) Gupta AK, Fleckman P, Baran R: Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 43(4 Suppl): S70-80, 2000.","DOI":"10.1067\/mjd.2000.109071"},{"key":"12","doi-asserted-by":"crossref","unstructured":"14) Saner MV, Kulkarni AD, Pardeshi CV: Insights into drug delivery across the nail plate barrier. J Drug Target 22: 769-789, 2014.","DOI":"10.3109\/1061186X.2014.929138"},{"key":"13","doi-asserted-by":"crossref","unstructured":"15) Khengar RH, Jones SA, Turner RB, Forbes B, Brown MB: Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers. Pharm Res 24: 2207-2212, 2007.","DOI":"10.1007\/s11095-007-9368-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"16) Elewski BE: Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 11: 415-429, 1998.","DOI":"10.1128\/CMR.11.3.415"},{"key":"15","doi-asserted-by":"crossref","unstructured":"17) EJ van Hoogdalem, WE van den Hoven, IJ Terpstra, J van Zijtveld, JSC Verschoor, JN Visser: Nail penetration of the antifungal agent oxiconazole after repeated topical application in healthy volunteers, and the effect of acetylcysteine. Eur J Pharm Sci 5: 119-127, 1997.","DOI":"10.1016\/S0928-0987(97)00270-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"18) Uchida K, Nishiyama Y, Yamaguchi H: <I>In vitro<\/I> antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 10: 216-219, 2004.","DOI":"10.1007\/s10156-004-0327-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"19) Koga H, Tsuji Y, Inoue K, Kanai K, Majima T, Kasai T, Uchida K, Yamaguchi H: <I>In vitro<\/I> antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother 12: 163-165, 2006.","DOI":"10.1007\/s10156-006-0440-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"20) Koga H, Nanjoh Y, Makimura K, Tsuboi R: <I>In vitro<\/I> antifungal activities of luliconazole, a new topical imidazole. Med Mycol 47: 640-647, 2009.","DOI":"10.1080\/13693780802541518"},{"key":"19","doi-asserted-by":"crossref","unstructured":"21) Shimamura T, Miyamae A, Arai M, Minemura A, Nozawa A, Kubota N: Distribution of luliconazole in nail plate by <I>In Vitro<\/I> permeation and efficacy by zone of inhibition test after treatment of luliconazole nail solution. Med Mycol J 57: J19-25, 2016.","DOI":"10.3314\/mmj.57.J19"},{"key":"20","doi-asserted-by":"crossref","unstructured":"23) Maeda J, Nanjoh Y, Koga H, Toga T, Makimura K, Tsuboi R: <I>In vitro<\/I> antifungal activity of luliconazole against <I>Trichophyton<\/I> spp. Med Mycol J 57: J1-6, 2016.","DOI":"10.3314\/mmj.57.J1"},{"key":"21","unstructured":"24) Murdan S: Nail disorders in older people, and aspects of their pharmaceutical treatment. Int J Pharm. pii: S0378-5173(16)30402-1, 2016. [Epub ahead of print]"},{"key":"22","doi-asserted-by":"crossref","unstructured":"25) Watanabe S: Present state and future direction of topical antifungals. Nihon Ishinkin Gakkai Zasshi 40: 151-155, 1999.","DOI":"10.3314\/jjmm.40.151"},{"key":"23","doi-asserted-by":"crossref","unstructured":"27) Matsuda Y, Sugiura K, Hashimoto T, Ueda A, Konno Y, Tatsumi Y: Efficacy coefficients determined using nail permeability and antifungal activity in keratin-containing media are useful for predicting clinical efficacies of topical drugs for onychomycosis. PLoS One 11: e0159661, 2016.","DOI":"10.1371\/journal.pone.0159661"},{"key":"24","doi-asserted-by":"crossref","unstructured":"28) Lusiana, Reichl S, M&uuml;ller-Goymann CC: Infected nail plate model made of human hair keratin for evaluating the efficacy of different topical antifungal formulations against <I>Trichophyton rubrum in vitro<\/I>. Eur J Pharm Biopharm 84: 599-605, 2013.","DOI":"10.1016\/j.ejpb.2013.01.015"},{"key":"25","unstructured":"29) Monti D, Tampucci S, Chetoni P, Burgalassi S, Mailland F: Ciclopirox vs amorolfine: <I>in vitro<\/I> penetration into and permeation through human healthy nails of commercial nail lacquers. J Drugs Dermatol 13: 143-147, 2014."},{"key":"26","doi-asserted-by":"crossref","unstructured":"30) Gupta AK, Daigle D, Paquet M: Therapies for onychomycosis a systematic review and network meta-analysis of mycological cure. J Am Podiatr Med Assoc 105: 357-366, 2015.","DOI":"10.7547\/13-110.1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"34) Watanabe S, Igarashi A, Katoh T, Matsuda T, Yamada K, Nishimoto K: Efficacy and safety of efinaconazole shown in Japanese patients with onychomycosis in the phase 3 global clinical trial. Nishinihon J Dermatol 77: 256-264, 2015.","DOI":"10.2336\/nishinihonhifu.77.256"}],"container-title":["Medical Mycology Journal"],"original-title":["\u5916\u7528\u722a\u767d\u766c\u6cbb\u7642\u85ac\u306e\u7279\u6027\u6bd4\u8f03"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/57\/4\/57_16-00020\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T01:30:51Z","timestamp":1568597451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/57\/4\/57_16-00020\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3314\/mmj.16-00020","relation":{},"ISSN":["2185-6486","2186-165X"],"issn-type":[{"value":"2185-6486","type":"print"},{"value":"2186-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}